english.prescrire.org > Spotlight > Archives : 2021 > In the June issue of Prescrire International: Non-metastatic, castration-resistant prostate cancer

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2021 : 1 | 30 | 60

In the June issue of Prescrire International: Non-metastatic, castration-resistant prostate cancer

FREE DOWNLOAD Survival extended with the addition of apalutamide or enzalutamide.
Full text available for free download.

Summary

  • After longer follow-up, an analysis of two placebo-controlled trials, one of which evaluated apalutamide and the other enzalutamide, has shown that median survival was extended by about one year when one of these drugs was added to medical or surgical castration in patients at high risk of developing prostate cancer metastases.
     
  • This clinical benefit was accompanied by an increase in serious, or even fatal, adverse effects.

©Prescrire 1 June 2021

Source: "Non-metastatic, castration-resistant prostate cancer. Survival extended with the addition of apalutamide or enzalutamide" Prescrire International 2021; 30 (227): 161. Free.

Enjoy full access to Prescrire International, and support independent information

Share
Share on  Facebook Share on  Twitter
 

Read more:

All the subjects in
Prescrire's Spotlight
Free >